Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368874 | 1.00 | CYP1A2 (0.48) | CYP1A2HRH3NAAAHRH4TLR7 | |
| SCHEMBL14368866 | 1.00 | CYP1A2 (0.48) | CYP1A2HRH3NAAAHRH4TLR7 | |
| Hydrochloric Acid SCHEMBL4428581 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| SCHEMBL7593657 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| Hydrochloric Acid SCHEMBL4422978 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| SCHEMBL19578854 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| Hydrochloric Acid SCHEMBL4426631 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| SCHEMBL8948236 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| SCHEMBL22857512 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 | |
| Propane SCHEMBL11130919 | 0.98 | CYP1A2 (0.47) | CYP1A2HRH3NAAAHRH4TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| US-20230407244-A1 | MICROBIAL GROWTH-STIMULATING PROTEIN AND METHODS OF USING SAME | PARADIGM DIAGNOSTICS, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230303591-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-09-28 | — | — | US | disclosed |
| US-11732285-B2 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022093775-A1 | MICROBIAL GROWTH-STIMULATING PROTEIN AND METHODS OF USING SAME | PARADIGM DIAGNOSTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-10813911-B2 | Methods of treating and/or preventing chronic obstructive pulmonary disease | UNIV BORDEAUX (FR) | 2020-10-27 | — | — | US | disclosed |
| US-20200208099-A1 | SELECTIVE ENRICHMENT MEDIA AND USES THEREOF | PARADIGM DIAGNOSTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111072550-A | Nilapari important intermediate and enzyme catalytic synthesis method thereof | 苏州凯瑞医药科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-10619130-B1 | Selective enrichment media and uses thereof | PARADIGM DIAGNOSTICS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-1305048-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | Wockhardt Limited (IN) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | disclosed |
| US-6451842-B1 | Cyclic amine derivatives and their use as drugs | DUPONT PHARMACEUTICALS COMPANY | 2002-09-17 | — | — | US | disclosed |
| US-6410566-B1 | ATHEROSCLEROSIS; ANTIARTHRITIC AGENTS | TEIJIN LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6362177-B1 | INHIBITION OF CHEMOKINE BINDING | TEIJIN LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| WO-2002009758-A2 | INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES | WOCKHARDT LIMITED (IN) | 2002-02-07 | — | — | WO | disclosed |
| CN-1279668-A | Cyclic amine derivatives and their use as pharmaceuticals | TEIJIN LTD (JP) | 2001-01-10 | — | — | CN | disclosed |
| WO-2000069815-A1 | UREIDO-SUBSTITUTED CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUG | TEIJIN LIMITED (JP) | 2000-11-23 | — | — | WO | disclosed |
| EP-0077607-A1 | N-substituted 3-aryl piperidines and derivatives thereof | BEECHAM GROUP PLC (GB) | 1983-04-27 | — | — | EP | disclosed |
| EP-0034471-A1 | Piperidinoquinazolines and a process for the preparation thereof | ORION-YHTYMÄ OY (FI) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303591-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4452/4885HRH3 3676/4885NAAA 3957/4885 |
| US-20020177559-A1 | Quinolone derivatives | ABCB11, ABCB1, ABCG2 | CYP1A2 357/4885HRH3 3952/4885NAAA 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.